Johnson & Johnson (JNJ) posted a mixed𝕴 first-quarter earnings Tuesday, and raised its🔯 dividend while narrowing full-year guidance for 2024.

Sales narrowly missed expectations, with Johnson & Johnson posting $21.38 billion in 澳洲幸运5官方开奖结果体彩网:total sales, shy of the $21.44 billion analysts expected, according to estimates compiled by Visible Alpha. The healthcare technology and pharmaceutical giant also reported adjusted 澳洲幸运5官方开奖结果体彩网:net income of $6.58 billion, or $2.71 澳洲幸运5官方开奖结果体彩网:per share, beating estimates of $6.39 billion and $2.62 per share, respectively.

Revenue increased 2.3% from last year's first-quarter mark of $20.89 billion, with adjusted income and EPS rising 3.8% and 12.4%, respectively, from last year's figures of $6.34 billion and $2.41 per share.

The company also increased its dividend for the 62nd straight year, bumping it 4.2% to $1.24 per share from $1.19 per share, for a yearly payout of $4.96. The next quarterly dividend will be paid June 4 to shareholders of record on May 21, Johnson & Johnson said.

Johnson & Johnson narrowed the range of its full-year sales guidance to between $88 billion and $88.4 billion from the $87.8 billion to $88.6 billion range it projected in January. Adjusted EPS was also narrowed slightly, to a range of $10.57 to $10.72💫 from $10.55 to $10.75.

Tuesday's report kicks off Johnson & Johnson's first full fiscal year after 澳洲幸运5官方开奖结果体彩网:completing its split last year that 澳洲幸运5官方开奖结果体彩网:separated its consumer brands like Band-Aid, Tylenol, and Listerine from the company's two other sectors, a change it 澳洲幸运5官方开奖结果体彩网:first announced in 2021. The consumer brands became Kenvue (KVUE), while the Johnson & Johnson name was🥃 retained for the medical technology and pharmaceutical divisions.

Johnson & Johnson's sales increased 7.8% in the U.S. compared to the first quarter of 2023, while international sales fell about 3.4%. The company has spent billions on a number of 澳洲幸运5官方开奖结果体彩网:acquisitions already in 2024, including 澳洲幸运5官方开奖结果体彩网:Ambrx Biopharma and 澳洲幸运5官方开奖结果体彩网:Shockwave Medical as Johnson & Johnson works to expand its offerings in the cancer drug and cardiovascular sectors, respectively.🤪

Johnson & John🉐son stock slipped about 2% to $144.60 as of 10:08 a.m✤. ET, and is down almost 10% so far this year.